Project Grant HT9425261E433
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- The Defense Health Agency awarded the University of California, Los Angeles $528,641 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate extracellular vesicles as biomarkers in non-Hodgkin lymphoma. The award funds research activities through June 30, 2028, with performance at UCLA's Los Angeles campus. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care...
- The Defense Health Agency awarded the University of California, Los Angeles $1,699,869 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct functional evaluation and optimization of CAR-T cells targeting prostate cancer through cell-cell interaction profiling using engineered nanovials. Work is performed in Los Angeles, California, with a period of performance through June 30, 2029. The Military Medical Research and Development program supports...
- The Defense Health Agency awarded University of California, San Diego $1.65 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. The award is a Project Grant with a period of performance from May 1, 2026, through April 30, 2029. Work is performed in La Jolla, California. The Military Medical Research and Development...
- The Defense Health Agency awarded the University of California Irvine $750,000 on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a novel strategy to improve the effectiveness of radiation therapy in breast cancer. The award funds research activity from May 1, 2026, through April 30, 2029, with place of performance in Irvine, California. The Military Medical Research and Development program supports basic, applied, and advanced biomedical...
- The Defense Health Agency awarded the University of California, Los Angeles $350,000 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a PLA-based, IHC-compatible functional assay for detection of homologous recombination deficiency in ovarian cancer. The award supports basic and applied biomedical research through the Defense Health Program with a period of performance through September 29, 2028. Work is performed at UCLA's Los...
- The Defense Health Agency awarded the University of California, Los Angeles $1.749996 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on adeno-associated virus-associated liver toxicity, biomarkers, and immune mechanisms to enable safer gene therapies. Research will be performed in Los Angeles, California, with a period of performance through August 31, 2029. The project grant is structured as a basic and applied...
- The Defense Health Agency awarded the University of California Irvine $140,000 on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate SUMO-specific protease 3 as a novel target for improving actinomycin D-based therapies in Wilms tumors. The award is a Project Grant with a period of performance from September 15, 2026, through September 14, 2028. Work is performed in Irvine, California. The Military Medical Research and Development program...
- The Defense Health Agency awarded the University of California Irvine $559,976 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate targeting mechanosensing Piezo1 channels of CD8 T cells to improve melanoma tumor immunity. Performance occurs at UC Irvine in Irvine, California, with a period of performance through August 31, 2028. The Military Medical Research and Development program funds basic, applied, and advanced biomedical...
- The Defense Health Agency awarded the University of California, Los Angeles $799,999 on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to link morphometry, clinical, and molecular data for drug response prediction. Work is performed in Los Angeles, California, with a period of performance through April 30, 2030. This administrative modification changes the log number from OC250702 to OC250532 and updates Division I items in the award terms and conditions.
- The Defense Health Agency awarded University of California, Los Angeles $7,999,212 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1 single-blind, placebo-controlled, dose escalation study evaluating the safety of AD-NP1, a humanized monoclonal antibody targeting human ENPP1. Work is performed in Los Angeles, California, with a period of performance through July 31, 2030. UCLA's Office of Research Administration serves as the...